×
About 195 results

ALLMedicine™ Hyperglucagonemia Center

Research & Reviews  73 results

Hyperglucagonemia Does Not Explain the β-Cell Hyperresponsiveness and Insulin Resistanc...
https://doi.org/10.2337/dc21-0460
Diabetes Care; Kahn SE, Mather KJ et. al.

Jun 17th, 2021 - To determine whether β-cell hyperresponsiveness and insulin resistance in youth versus adults in the Restoring Insulin Secretion (RISE) Study are related to increased glucagon release. In 66 youth and 350 adults with impaired glucose tolerance (IG...

Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1...
https://doi.org/10.2337/db20-0998
Diabetes Bagger JI, Grøndahl MFG et. al.

Mar 17th, 2021 - Hyperglucagonemia is a well-known contributor to diabetic hyperglycemia, and glucagon-like peptide 1 (GLP-1) suppresses glucagon secretion. Reduced inhibitory effects of glucose and GLP-1 on glucagon secretion may contribute to the hyperglucagonem...

Glucagon Resistance and Decreased Susceptibility to Diabetes in a Model of Chronic Hype...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881862
Diabetes Bozadjieva Kramer N, Lubaczeuski C et. al.

Nov 27th, 2020 - Elevation of glucagon levels and increase in α-cell mass are associated with states of hyperglycemia in diabetes. Our previous studies have highlighted the role of nutrient signaling via mTOR complex 1 (mTORC1) regulation that controls glucagon se...

A Review of the Efficacy and Cardiovascular Safety of Amylin Analogues.
https://doi.org/10.2174/1574886315999201105153852
Current Drug Safety; Koshy RM, Fernandez CJ et. al.

Nov 7th, 2020 - A large proportion of persons with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) do not reach the glycosylated haemoglobin (HbA1c) target of < 7% (53 mmol/- mol), with an increasing proportion of them being overweight or obes...

Association of Glucagon With Obesity, Glycemic Control and Renal Function in Adults Wit...
https://doi.org/10.1016/j.jcjd.2020.08.108
Canadian Journal of Diabetes; Hamasaki H, Morimitsu S

Nov 2nd, 2020 - In this study, we used a double-antibody sandwich enzyme-linked immunosorbent assay to assess the association between blood glucagon levels and indices of obesity, glycemic control and renal function in patients with type 2 diabetes mellitus (T2DM...

see more →

Clinicaltrials.gov  4 results

Effects of Metreleptin in Type 1 Diabetes Mellitus
https://clinicaltrials.gov/ct2/show/NCT01268644

Aug 28th, 2019 - The adipocyte hormone, leptin, has been shown to restore the health and glucoregulation of near-death, insulin deficient diabetic rodents. This makes leptin the only hormone, since the discovery of insulin in 1922, with this capability. Leptin nor...

GLP-1 Effects on Insulin and Glucagon in PTDM
https://clinicaltrials.gov/ct2/show/NCT02591849

Mar 31st, 2016 - Post-transplantation diabetes mellitus (PTDM) develops in 10-15 % of all renal transplant recipients within 10 weeks after transplantation, and has been associated with increased risk of cardiovascular disease and impaired patient survival. PTDM i...

GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia
https://clinicaltrials.gov/ct2/show/NCT00716170

Nov 28th, 2013 - Patients with T2DM are not able to suppress their secretion of glucagon after a meal or after oral ingestion of glucose. Patients actually respond with pathological high plasmaglucagon concentrations to these stimuli. Previous studies have shown t...

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes
https://clinicaltrials.gov/ct2/show/NCT00505882

May 11th, 2009 - The autoimmune process along with a strong genetic-mediated destruction and dysfunction of pancreatic β-cells are the main pathogeneses of type 1 diabetes. These processes cause absolute and relative insulin and amylin deficiencies. For the last d...

see more →

News  1 results

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
https://www.medscape.com/viewarticle/850125

Abstract and Introduction Abstract Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ketoacidosis (euDKA) in ...

see more →